Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed/Refractory Mantle Cell Lymphoma in the Post-Marketing Setting
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Observational
SUMMARY
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• • Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA
Locations
United States
Wisconsin
Center for International Blood and Marrow Transplant Research (CIBMTR)
RECRUITING
Milwaukee
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2025-02-04
Estimated Completion Date: 2044-09-30
Participants
Target number of participants: 300
Treatments
Participants treated with lisocabtagene maraleucel
Related Therapeutic Areas
Sponsors
Leads: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company